Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting.
about
Synthetic DNA vaccine strategies against persistent viral infectionsEnhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed miceExpression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccinesProgress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles.DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice.Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routesAntibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1.Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting.C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequencesPurification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d.Mucosal application of gp140 encoding DNA polyplexes to different tissues results in altered immunological outcomes in mice.Comparison of immune response generated against Japanese encephalitis virus envelope protein expressed by DNA vaccines under macrophage associated versus ubiquitous expression promotersEnhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins.What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses.Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants.A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially.Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primatesA pilot study comparing the development of EIAV Env-specific antibodies induced by DNA/recombinant vaccinia-vectored vaccines and an attenuated Chinese EIAV vaccineStrong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus VaccinePrevention of the sexual transmission of HIV-1: preparing for success.Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.Heterologous prime-boost vaccination.DNA Immunization for HIV Vaccine Development.How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses.Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunitsEvidence for similar recognition of the conserved neutralization epitopes of human immunodeficiency virus type 1 envelope gp120 in humans and macaques.DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques.Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate.One Group's Historical Reflections on DNA Vaccine Development
P2860
Q27016078-71CED5A6-04B6-4C80-A8C9-838990A800CBQ27469642-93AF8D42-F4B9-4926-A88F-6A7EA155B2C5Q30332833-2C48CFAC-ED2E-49E3-8A98-D6652ED09863Q30379200-D35F3077-E8CB-4481-A4AA-00C70097B956Q30418340-C34FC8DA-0407-46FE-9BFC-3E69F5E399A3Q33647708-E010CD69-621E-44D7-9E9F-1F93315F32A7Q33743758-AC95951C-E7F8-48D1-A805-B58CF975BD2AQ33759392-72B0CFCC-88CC-4B2D-A91D-7467BD13E5AEQ33843103-FF8D4287-4B98-4672-BEE0-635D1954BA73Q34007261-30B5A210-8CAE-4B83-B167-F5BAAF938E7FQ34099087-6C3B3A33-32F9-4DDA-A265-165673D8A543Q34332284-2E5F9071-C95D-4290-B0DB-D5B29A7204BAQ34466693-8A8DE1E4-13B4-47E9-B026-0C61A6820FAEQ34797176-4099815C-91FC-4B6C-A918-67C89B8F7DC3Q35179151-3088A73D-77FB-4DB5-A355-AD5B6D572788Q35613328-8D314E0D-1ECE-43AC-9B6C-23C540BE5D32Q35641144-2A17AF44-B97F-4AFE-8F1E-1AD98ED42D93Q35754196-179A6602-FA06-4BFF-8C33-33269014378BQ36119504-4CB96801-AF15-469A-B8F1-972EABB31A33Q36149102-4ADF9E8D-82E2-44BD-A83C-1D0E329E18B5Q36249053-6737BA80-AA8D-44AC-82FC-9F8F673B2684Q36438450-E10509C3-2267-4E6D-86D9-E857029BB3AEQ36456552-1E1859A1-FA17-4261-89C2-BB09A86E1CE3Q36708266-C4EB7E23-B76E-4AFA-A68C-6D9469C4D4B9Q36975282-E5C2B4D4-282B-4A9F-A384-5BA05401CB01Q37422543-229CE806-557F-4188-ABBD-5C6CF9DCAE50Q37509586-516B1F97-75E6-4228-A3A3-CB111DED675AQ38581981-9E8EDA9B-A5FE-4B58-863F-208E8690D7C2Q38618790-D9338CAD-AA56-4B7D-82A6-C8BEF9B5C8A8Q39585034-C4691887-A020-4898-AB4F-E32A1D30E065Q39604142-244EB6AB-9BDD-47B5-BACC-45CA555C429DQ40904272-3255E46C-7984-4151-9AF1-D0AD0412E89BQ42054413-E2072C23-C0EA-4B62-AD47-77C5F3574B28Q58731456-FBD5F55C-51BE-49A9-91A3-3606BDAC1688
P2860
Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting.
description
1998 nî lūn-bûn
@nan
1998 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Studies of the neutralizing ac ...... priming and protein boosting.
@ast
Studies of the neutralizing ac ...... priming and protein boosting.
@en
type
label
Studies of the neutralizing ac ...... priming and protein boosting.
@ast
Studies of the neutralizing ac ...... priming and protein boosting.
@en
prefLabel
Studies of the neutralizing ac ...... priming and protein boosting.
@ast
Studies of the neutralizing ac ...... priming and protein boosting.
@en
P2093
P2860
P1433
P1476
Studies of the neutralizing ac ...... priming and protein boosting.
@en
P2093
D C Montefiori
H L Robinson
J C Santoro
J F Richmond
P2860
P304
P577
1998-11-01T00:00:00Z